Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1. Tan ST, Boyle V, Elston MS. Hypertension 2023;80:1517-1525.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tan ST, Boyle V, Elston MS. Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1. Hypertension 2023;80:1517-1525.
PMID: 37170822